~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~
~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI™ in Europe, Australia and New Zealand for Approximately $43 Million Upfront and Up to Approximately $230 Million in Additional Commercial and Regulatory Milestones, and Tiered Royalties Up to the Mid-Twenties ~ ~ Pro forma fourth quarter cash in excess of $55 million ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the fiscal year ended December 31, 2023 and provided a business update. “It was an exciting year for Fennec given the strong performance with PEDMARK® in the first full fiscal year following its U.S. commercial launch. We are pleased with our execution against strategic plans and our momentum in 2023, which sets the stage for further success in 2024 and beyond. We also received European Commission and U.K. approvals of PEDMARQSI™, which led to the recent announcement of an exclusive licensing agreement with Norgine for Europe, Australia and New Zealand,” said Rosty Raykov, Chief Executive Officer of Fennec Pharmaceuticals. “We have significantly strengthened our balance sheet through the agreement with Norgine, and we remain dedicated to further growing our revenues as we expand the availability of PEDMARK® to patients and providers globally.” Recent Developments and Highlights: - Entered into exclusive licensing agreement to commercialize PEDMARQSI™ in Europe, Australia and New Zealand. Fennec received approximately $43 million upfront and has the potential to receive up to approximately $230 million in additional commercial and regulatory milestones, and double-digit tiered royalties up to the mid-twenties. PEDMARQSI was granted EU marketing authorization by the European Commission in June 2023, and received UK approval from the MHRA in October 2023.
- Achieved PEDMARK net product revenue of approximately $9 million and $21 million for the fourth quarter and full year 2023, respectively. Additionally, anticipate continued increasing utilization of the earlier endorsement from the NCCN for PEDMARK® in the adolescent and young adult (AYA) population.
- In January 2024, the FDA issued a public reminder to healthcare providers that PEDMARK (sodium thiosulfate injection) is not substitutable with other sodium thiosulfate products as explicitly directed in its prescribing label.
Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2023 - Net Sales – Net product sales of $21.3 million in fiscal 2023 compared to $1.5 million in 2022. The Company had gross profit of $20.0 million for fiscal year ended 2023. The increase in sales reflects strong growth in new patient starts and accounts.
- Cash Position – Cash and cash equivalents were $13.2 million as of December 31, 2023. There was a $10.5 million decrease in cash and cash equivalents between December 31, 2023 and December 31, 2022 as a result of cash outlays for operating expenses related to the promotion and marketing of PEDMARK®, general and administrative expenses and the preparation for the commercial launch of PEDMARQSI in Europe. These cash outflows were offset by cash inflows primarily from product sales. In addition, as announced this week, we received approximately $43 million from the licensing of Europe, Australia and New Zealand to Norgine. Inclusive of these events, the pro forma December 31, 2023 cash balance is in excess of $55 million. We anticipate that our cash, cash equivalents and investment securities as of December 31, 2023, when coupled with PEDMARK revenue assumptions and the recently announced license agreement for Europe, will be sufficient to fund our planned operations for at least the next twelve months.
- Research and Development Expenses (R&D) Expenses – R&D expenses decreased by $3.5 million in fiscal 2023 as compared to fiscal 2022. The Company reduced research and development costs when it received FDA approval of PEDMARK® in September 2022. The majority of traditional research and development expenses associated with PEDMARK® are now recorded as general and administrative expenses or capitalized into inventory and eventually recorded to costs of product sales.
- Selling and Marketing Expenses – Selling and marketing expenses include remuneration of our sales and marketing employees, dollars spent on marketing campaigns (sponsorships, trade shows, presentations, etc.), and any activities to support marketing and sales activities. The Company recorded $12.1 million in selling and marketing expenses in fiscal 2023, compared to $2.8 million in fiscal year 2022.
- General and Administrative (G&A) Expenses – For fiscal 2023, G&A expenses increased by $2.3 million compared to fiscal 2022. Non-cash expenses associated with equity remuneration increased by $1.4 million in fiscal year 2023 over 2022. Payroll and benefits related expenses rose by $1.1 million in fiscal 2023 compared to fiscal 2022. There was an increase in consulting and professional costs of $0.8 million in fiscal 2023 over fiscal 2022.
- Net Loss – Net losses for the fourth quarter and year ended December 31, 2023, of $2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively, compared to $6.9 million ($0.26 per share) and $23.7 million ($0.90 per share), respectively, for the same periods in 2022.
Financial Update The selected financial data presented below is derived from our unaudited, condensed consolidated financial statements, which were prepared in accordance with U.S. generally accepted accounting principles. The complete audited, condensed consolidated financial statements for the period ended December 31, 2023, and management's discussion and analysis of financial condition and results of operations, will be available via www.sec.gov and www.sedar.com. All values are presented in thousands unless otherwise noted. | Unaudited Consolidated | Statements of Operations: | (U.S. Dollars in thousands except per share amounts) | | | | | | | | | | | | | | | Three Months Ended | | | Twelve Months Ended | | December 31, | | December 31, | | | December 31, | | December 31, | | 2023
| | 2022
| | | 2023 | | 2022
| | | | | | | | | | | | | | Revenue | | | | | | | | | | | | | PEDMARK product sales, net | $ | 9,735 | | | $ | 1,535 | | | | $ | 21,252 | | | $ | 1,535 | | Cost of products sold | | (685 | ) | | | (86 | ) | | | | (1,259 | ) | | | (86 | ) | Gross profit | | 9,050 | | | | 1,449 | | | | | 19,993 | | | | 1,449 | | | | | | | | | | | | | | | Operating expenses: | | | | | | | | | | | | | Research and development | | 32 | | | | 117 | | | | | 56 | | | | 3,531 | | Selling and marketing | | 3,868 | | | | 2,785 | | | | | 12,123 | | | | 2,785 | | General and administrative | | 6,968 | | | | 4,682 | | | | | 20,585 | | | | 17,722 | | | | | | | | | | | | | | | Total operating expenses | | 10,868 | | | | 7,584 | | | | | 32,764 | | | | 24,038 | | Loss from operations | | (1,818 | ) | | | (6,135 | ) | | | | (12,771 | ) | | | (22,589 | ) | | | | | | | | | | | | | | Other (expense)/income | | | | | | | | | | | | | Unrealized foreign exchange gain (loss) | | 2 | | | | (58 | ) | | | | 5 | | | | (9 | ) | Amortization expense | | (70 | ) | | | (70 | ) | | | | (287 | ) | | | (149 | ) | Unrealized gain (loss) on securities | | 4 | | | | (3 | ) | | | | (39 | ) | | | (184 | ) | Interest income | | 115 | | | | 153 | | | | | 441 | | | | 195 | | Interest expense | | (915 | ) | | | (744 | ) | | | | (3,394 | ) | | | (978 | ) | Total other (expense)/income | | (864 | ) | | | (722 | ) | | | | (3,274 | ) | | | (1,125 | ) | | | | | | | | | | | | | | Net loss | $ | (2,682 | ) | | $ | (6,857 | ) | | | $ | (16,045 | ) | | $ | (23,714 | ) | | | | | | | | | | | | | | Basic net loss per common share | $ | (0.10 | ) | | $ | (0.26 | ) | | | $ | (0.60 | ) | | $ | (0.90 | ) | Diluted net loss per common share | $ | (0.10 | ) | | $ | (0.26 | ) | | | $ | (0.60 | ) | | $ | (0.90 | ) | Weighted-average number of common shares outstanding, basic | | 26,833 | | | | 26,275 | | | | | 26,574 | | | | 26,275 | | Weighted-average number of common shares outstanding, diluted | | 26,833 | | | | 26,275 | | | | | 26,574 | | | | 26,275 | |
Unaudited Consolidated Balance Sheets: | (U.S. Dollars in thousands) | | | | | | | | | | December 31, | | December 31, | | | 2023 | | 2022 | | | | | | | | Assets | | | | | | | | | | | | | | Current assets | | | | | | | Cash and cash equivalents | | $ | 13,269 | | | $ | 23,774 | | Accounts receivable, net | | | 8,814 | | | | 1,545 | | Prepaid expenses | | | 583 | | | | 770 | | Inventory | | | 2,156 | | | | 576 | | Other current assets | | | 21 | | | | 63 | | Total current assets | | | 24,843 | | | | 26,728 | | | | | | | | | Non-current assets | | | | | | | Deferred issuance cost, net amortization | | | 2,021 | | | | 211 | | Total non-current assets | | | 2,021 | | | | 211 | | Total assets | | $ | 26,864 | | | $ | 26,939 | | | | | | | | | Liabilities and shareholders’ (deficit) equity | | | | | | | | | | | | | | Current liabilities: | | | | | | | Accounts payable | | $ | 3,799 | | | $ | 2,390 | | Accrued liabilities | | |
|
Related companies: | Adherex Technologies, Inc. |
|